Eloralintide is an investigational once-weekly injectable amylin receptor agonist being developed by Lilly for obesity and overweight management. Clinical data have been reported from Phase 1 and Phase 2 studies, with Phase 3 progression plans described by the sponsor. The drug is not FDA-approved.
AbbVie shares declined 2% on March 13, 2026, amid reduced trading volume, while BMO Capital maintained its Outperform rating following Phase 1 obesity drug trial data for ABBV-295.
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589608 |
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight |
NOT_YET_RECRUITING | PHASE2 |
| NCT07392190 |
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin |
RECRUITING | PHASE3 |
| NCT07369011 |
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
RECRUITING | PHASE3 |
| NCT07353931 |
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight |
RECRUITING | PHASE3 |
| NCT07321886 |
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes |
RECRUITING | PHASE3 |
| NCT07282600 |
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes |
RECRUITING | PHASE3 |
| NCT07215559 |
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes |
RECRUITING | PHASE2 |
| NCT06916091 |
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight |
COMPLETED | PHASE1 |
| NCT06916065 |
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity |
COMPLETED | PHASE1 |
